Brief: GT Biopharma Advances GTB-3650 Phase 1 Trial to Cohort 2 Following Successful Initial Human Dosing and Evidence of Early Immune Activation Signals
19/05/2025 14:06
May 19 (Reuters) - GT Biopharma Inc GTBP.O: GT BIOPHARMA ADVANCES GTB-3650 PHASE 1 TRIAL TO COHORT 2 FOLLOWING SUCCESSFUL INITIAL HUMAN DOSING AND EVIDENCE OF EARLY IMMUNE ACTIVATION SIGNALS GT BIOPHARMA INC - NO SAFETY ISSUES IN COHORT 1, COHORT 2 PROCEEDS GT BIOPHARMA INC - DETAILED PHASE 1 RESULTS EXPECTED LATER IN 2025 Source text: ID:nGNXnxzFt Further company coverage: GTBP.O ((Reuters.Briefs@thomsonreuters.com;))